Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylprednisolone sodium succinate
Drug ID BADD_D01436
Description A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
Indications and Usage Adjunctive therapy for short-term administration in rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB14644
KEGG ID D00751
MeSH ID D008776
PubChem ID 23680530
TTD Drug ID Not Available
NDC Product Code 0009-0698; 0009-0047; 0009-0758; 63323-265; 68071-1792; 55150-263; 63323-258; 0009-0039; 55150-265; 55154-3941; 0009-0850; 50090-0271; 55154-3944; 63323-255; 71872-7061; 0143-9851; 55150-262; 0143-9850; 70518-2023; 71872-7232; 52584-039; 70518-3128; 0404-9958; 0009-0003; 55154-3939; 55154-3940; 55150-264; 0404-9957; 0009-0018; 52584-047
Synonyms Methylprednisolone Hemisuccinate | Hemisuccinate, Methylprednisolone | Methylprednisolone Succinate | Succinate, Methylprednisolone | Urbason-Soluble | UrbasonSoluble | Solu-Medrol | Solumedrol | A-MethaPred | Methylprednisolone Sodium Succinate | Sodium Succinate, Methylprednisolone | Methylprednisolone Hemisuccinate Monosodium Salt | 6 alpha-Methylprednisolone Sodium Hemisuccinate | Methylprednisolone Sodium Hemisuccinate | Sodium Hemisuccinate, Methylprednisolone
Chemical Information
Molecular Formula C26H33NaO8
CAS Registry Number 2375-03-3
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)[O-])O.[Na+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Glucose tolerance decreased13.02.02.004--Not Available
Glycosuria20.02.01.005--
Headache17.14.01.001--
Hepatomegaly09.01.05.001--Not Available
Hiccups22.02.04.002; 07.01.06.009--
Hirsutism23.02.04.001; 05.05.01.005--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertrichosis23.02.04.002--
Hypertrophic cardiomyopathy03.07.02.004; 02.04.01.002--Not Available
Hypokalaemic syndrome14.05.03.003--Not Available
Hypopituitarism05.03.02.001--
Impaired healing08.03.02.001--Not Available
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Increased insulin requirement14.06.01.006; 05.06.01.006--Not Available
Infection susceptibility increased11.01.08.004; 10.02.01.046--Not Available
Injection site infection12.07.03.008; 11.01.08.005; 08.02.03.019--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intracranial pressure increased17.07.02.002--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Large intestine perforation12.02.03.005; 07.04.06.005--
Malaise08.01.01.003--
Menstruation irregular05.05.01.008; 21.01.01.005--
Mood swings19.04.03.001--Not Available
Muscle disorder15.05.03.014--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocardial rupture02.04.02.002; 12.01.11.002--Not Available
Myopathy15.05.05.001--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages